| 2017LS006 |
Immunotherapy - Drugs |
Phase I/II
|
HM2017-24 : Phase I/II Study of Nivolumab in Combination with Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma: BTCRC-HEM-027
|
| 2020IS054 |
Chemotherapy;Immunotherapy - C |
Phase I/II
|
MT2020-08 A Phase 1/1b Open-label, Dose-escalation, Dose-expansion, Parallel Assignment Study to Evaluate the Safety and Clinical Activity of PBCAR0191(azercabtagene zapreleucel or azer-cel), in Subjects with Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
|
| 2020LS100 |
Supportive Care |
Phase I/II
|
MT2020-27: Phase I/II Trial Using E7777 to Enhance Regulatory T-Cell Depletion Prior to CAR-T Therapy for Relapsed/Refractory Large B-Cell Lymphomas
|
| 2020LS098 |
|
Phase I/II
|
MT2020-28: Ruxolitinib, Human Chorionic Gonadotropin (uhCG/EGF), and Dose De-escalated Corticosteroids for Treatment of Minnesota High-Risk Acute GVHD (aGVHD): A Phase I/II Study
|
| 2021IS114 |
|
Phase I/II
|
A Phase 1/2 Study of [225Ac]-FPI-1434 Injection in Patients with Locally Advanced or Metastatic Solid Tumours
|
| 2021IS148 |
Combined Modality Therapy |
Phase I
|
HM2021-31: A Phase 1b Open-Label Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination with Other Anti-cancer Agents in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)
|
| 2021CG156 |
Chemotherapy;Supportive Care |
Phase I/II
|
PEPN2011 - A Phase 1/2 Study of Tegavivint (IND#156033, NSC#826393) in Children, Adolescents, and Young Adults with Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
|
| 2021IS173 |
|
Phase I
|
A Phase 1, First in Human, Dose-Escalation Study of TORL-1-23 in Participants with Advanced Cancer
|
| 2021IS174 |
|
Phase I/II
|
A Phase 1/2 Study of the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adult Participants with Recurrent or Refractory Classical Hodgkin Lymphoma and Non-Hodgkin Lymphoma
Protocol Number: CA224069
|
| 2022CG008 |
Chemotherapy;Supportive Care |
Phase I/II
|
PEPN2111 - A Phase 1/2 Trial of CBL0137 (NSC# 825802, IND# 155843) in Patients with Relapsed or Refractory Solid Tumors including CNS Tumors and Lymphoma
|
| 2022IS096 |
Blood and Marrow Transplant |
Phase I/II
|
MT2022-41: A Phase 1/2 Study Evaluating the Safety and Efficacy of a Single Dose of Autologous CD34+ Base Edited Hematopoietic Stem Cells (BEAM-101) in Patients with Sickle Cell Disease and Severe Vaso-Occlusive Crises (BEACON Trial)
|
| 2022CG158 |
|
Phase I
|
PEPN22P1: Pharmacokinetic Study of VinCRIStine in Infants Dosed According to BSA-Banded Infant Dosing Tables and Older Children Dosed by Traditional BSA Methods
|
| FVMMCORC-2022-WF1901 |
|
Phase I
|
Internet-delivered Management of Pain Among Cancer Treatment Survivors
|
| 2022UC137 |
|
Phase I
|
PRE-I-SPY TRIAL - PRE-Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging And moLecular Analysis: A Phase I/Ib platform trial
|
| 2022IS066 |
Combined Modality Therapy |
Phase I
|
A Phase 1b Open-Label Multicenter Study of OP-1250 (Palazestrant) in Combination with the CDK4/6 Inhibitor Ribociclib, with the PI3K Inhibitor Alpelisib, or with the mTOR inhibitor
Everolimus in Adult Subjects with Advanced and/or Metastatic ER Positive, HER2 Negative Breast Cancer
|
| 2022IS180 |
|
Phase I
|
MT2024-08: Phase I open-label, dose escalation trial of BI 1831169 monotherapy and in combination with an anti-PD-1 mAb in patients with advanced or metastatic solid tumors.
|
| 2023CG071 |
|
Phase I/II
|
A Phase 1B and randomized phase 2 trial of megestrol acetate with or without ipatasertib in recurrent or metastatic endometrioid endometrial cancer
|
| 2023LS024 |
|
Phase I
|
MT2023-05: GTB-3650 (anti-CD16/IL-15/anti-CD33) Tri-Specific Killer Engager (TriKEŽ) for the Treatment of High Risk Myelodysplastic Syndromes (MDS) and Refractory/Relapsed Acute Myeloid Leukemia (AML)
|
| SURG-2023-29833 |
|
Phase I
|
An Open-Label, Pilot Clinical Trial To Test The Safety And Feasibility Of Intestinal Microbiota Transplantation In Patients Undergoing Colon Resection
|
| 2021LS140 |
|
Phase I
|
Phase I Clinical Trial of Cell Based Therapy for Duchenne Muscular Dystrophy
|
| 2023IS006-T2 |
|
Phase I
|
MT2023-28: A Phase 1 Basket Study Evaluating the Safety and Feasibility of T-Plex,
Autologous Customized T Cell Receptor-Engineered T Cells Targeting
Multiple Peptide/HLA Antigens in Participants with Antigen-positive Locally
Advanced (Unresectable) or Metastatic Solid Tumors: PLEXI-T(TM)
|
| 2023IS006 |
|
Phase I
|
Screening Study to Determine HLA Type, HLA Loss of Heterozygosity Status and Tumor Antigen Expression in Participants with Locally Advanced (Unresectable) or Metastatic Solid Tumors
|
| 2023IS107 |
|
Phase I
|
MT2023-30: A Phase 1 Study of FT825/ONO-8250, an Off-the-Shelf CAR T-Cell Therapy, With or Without Monoclonal Antibodies, in HER2-Positive or Other Advanced Solid Tumors
|
| 2023IS178 |
|
Phase I
|
MT2023-42: A Phase 1 Study of FT819 in B-Cell Mediated Autoimmune DIseases
|
| 2022LS030 |
Other Cancer Treatment |
Phase I
|
A Phase I Study of a Tropism Modified Conditionally Replicative Adenovirus Vector (RGDCRAdCOX2F) for Endoscopic, Direct-Tumor Delivery in Pancreatic Adenocarcinoma
|
| 2023IS110 |
|
Phase I
|
Phase 1b/3 global, randomized, controlled, open-label trial comparing treatment with RYZ101 to standard of care (SoC) therapy in subjects with inoperable, advanced, somatostatin receptor expressing (SSTR+), well-differentiated gastro-enteropancreatic neuroendocrine tumors (GEP-NETs) that have progressed following prior 177Lu-labelled somatostatin analogue (177Lu-SSA) therapy (ACTION-1)
|
| 2023LS185 |
Immunotherapy - Cellular/Vacci |
Phase I
|
Intraperitoneal FT536 in Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
|
| 2023IS205 |
|
Phase I
|
MT2024-05: A Phase I, First in Human Open Label Study to Evaluate the Safety and Tolerability of TRX103 cell infusion in subjects with hematological malignancies undergoing HLA-mismatched related or unrelated hematopoietic stem cell transplantation (HSCT)
|
| 2024IS058 |
|
Phase I/II
|
A Phase 1B/2, Multicenter, Open-label Study of Ifinatamab Deruxtecan (I-DXd), A B7- H3 Antibody-Drug Conjugate (ADC), In combination with Atezolizumab with or Without Carboplatin as First Line Induction or Maintenance, In Subjects with Extensive-Stage Small Cell Lung Cancer (ES-SCLC) (IDeate-Lung03)
|
| 2024IS051 |
|
Phase I
|
MT2024-12: A Phase 1 Study Evaluating BAFFR-targeting CAR T cells for Patients with Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma (B-NHL)
|
| 2024IS070 |
|
Phase I/II
|
A first-in-human, Phase 1/2, open-label, multi-center, dose-escalation, dose-optimization, and dose-expansion study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and anti-tumor activity of PARP1 selective inhibitor, IMP1734, as monotherapy and in combination in participants with advanced solid tumors
|
| 2024IS074 |
|
Phase I
|
A Phase 1b, Open-label, Multicenter Study Evaluating the Safety, Tolerability, and Efficacy
of Xaluritamig in Subjects With High-risk Biochemical Recurrence of Nonmetastatic Castration-sensitive Prostate Cancer After Definitive Therapy
|
| 2024IS055 |
Immunotherapy - Drugs |
Phase I/II
|
HM2024-18 A Phase 1/2, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients with Intermediate or High-risk Primary or Secondary Myelofibrosis
|
| 2024CG120 |
|
Phase I
|
PEPN2312; A Phase 1 study of GRN163L (Imetelstat, IND# 170891, NSC# 754228) in combination with fludarabine and cytarabine for patients with acute myeloid leukemia that is in second or greater relapse or that is refractory to relapse therapy; myelodysplastic syndrome or juvenile myelomonocytic leukemia in first or greater relapse or is refractory to relapse therapy
|
| FVMMCORC-2024-NRGGY028 |
|
Phase I/II
|
NRG-GY028: A PHASE IB AND RANDOMIZED PHASE II TRIAL OF
MEGESTROL ACETATE WITH OR WITHOUT IPATASERTIB IN
RECURRENT OR METASTATIC ENDOMETRIOID ENDOMETRIAL
CANCER
|
| SURG-2024-33321 |
|
Phase I
|
An Open-Label, Pilot Clinical Trial To Test The Efficacy Of A Suspension of Freeze-dried Microbiota In Patients Undergoing Colon Resection
|
| IDIM-2024-33364 |
|
Phase I/II
|
Phase 1b/2a, Randomized, Double-blind Study to Investigate Safety, Tolerability, PK, PD, and Preliminary Efficacy of Oral Administration of SNIPR001 in Patients with Hematologic Malignancy Scheduled for Allogeneic Hematopoietic Stem-Cell Transplantation Receiving Fluoroquinolone Prophylaxis and Harboring Fluoroquinolone-Resistant Escherichia coli Pre-Transplant
|
| 2024IS116 |
|
Phase I
|
A Phase 1a/b Study of ADRX-0405 in Subjects with Select Advanced Solid Tumors
|
